<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Janus kinase 2 (JAK2)V617F-activating mutations (JAK2mu) occur in <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) </plain></SENT>
<SENT sid="1" pm="."><plain>Cell lines MB-02, MUTZ-8, SET-2 and UKE-1 carry JAK2V617F and derive from patients with <z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MPD/MDS</z:e> histories </plain></SENT>
<SENT sid="2" pm="."><plain>Challenging the consensus that expression of JAK2V617F is the sole precondition for cytokine independence in class I cytokine receptor-positive cells, two of four of the JAK2mu cell lines were growth factor-dependent </plain></SENT>
<SENT sid="3" pm="."><plain>These cell lines resembled JAK2wt cells regarding JAK2/STAT5 activation: cytokine deprivation effected dephosphorylation, whereas erythropoetin or granulocyte colony-stimulating factor induced phosphorylation of JAK2 and STAT5 </plain></SENT>
<SENT sid="4" pm="."><plain>Cytokine independence correlated with low expression and cytokine dependence with high expression of the JAK/STAT pathway inhibitor suppressor of cytokine signaling 2 (SOCS2) suggesting a two-step mechanism for cytokine independence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> cells: (i) activation of the oncogene JAK2V617F and (ii) inactivation of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene SOCS2 </plain></SENT>
<SENT sid="5" pm="."><plain>Confirming that SOCS2 operates as a negative JAK2V617F regulator, SOCS2 knockdown induced constitutive STAT5 phosphorylation in JAK2mu cells </plain></SENT>
<SENT sid="6" pm="."><plain>CpG island hypermethylation is reported to promote SOCS gene silencing in malignant diseases </plain></SENT>
<SENT sid="7" pm="."><plain>Accordingly, in one of two cytokine-independent cell lines and in two of seven <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> patients, we found SOCS2 hypermethylation associated with reduced promoter access to transcription factors </plain></SENT>
<SENT sid="8" pm="."><plain>Our results provide solid evidence that SOCS2 epigenetic downregulation might be an important second step in the genesis of cytokine-independent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> clones </plain></SENT>
</text></document>